Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jul 15;14(14):4358-67.
doi: 10.1158/1078-0432.CCR-08-0288.

Randomized Phase III Clinical Trial Designs for Targeted Agents

Affiliations
Free PMC article

Randomized Phase III Clinical Trial Designs for Targeted Agents

Antje Hoering et al. Clin Cancer Res. .
Free PMC article

Abstract

Purpose: Cancer therapies with mechanisms of action which are very different from the more conventional chemotherapies are now being developed. In this article, we investigate the performance of several phase III clinical trial designs, both for testing the overall efficacy of a targeted agent and for testing its efficacy in a subgroup of patients with a tumor marker present. We study different designs and different underlying scenarios assuming continuous markers, and assess the trade-off between the number of patients on the study and the effectiveness of treatment in the subgroup of marker-positive patients.

Experimental design: We investigate binary outcomes and use simulation studies to determine sample size and power for the different designs and the various scenarios. We also simulate marker prevalence and marker misclassification and evaluate their effect on power and sample size.

Results: In general, a targeted design which randomizes patients with the appropriate marker status performs the best in all scenarios with an underlying true predictive marker. Randomizing all patients regardless of their marker values performs as well as or better in most cases than a clinical trial that randomizes the patient to a treatment strategy based on marker value versus standard of care.

Conclusion: If there is the possibility that the new treatment helps marker-negative patients, or that the cutpoint determining marker status has not been well established and the marker prevalence is large enough, we recommend randomizing all patients regardless of marker values, but using a design such that both the overall and the targeted subgroup hypothesis can be tested.

Conflict of interest statement

Disclosure of Potential Conflicts of Interest No potential conflicts of interest were disclosed.

Figures

Fig. 1
Fig. 1
Possible clinical trial designs for targeted therapy: randomize-all design, targeted design, strategy design.
Fig. 2
Fig. 2
Scenarios for response distribution of marker. The response probability is plotted versus the log-transformed marker value x.
Fig. 3
Fig. 3
Power of the randomize-all, targeted, and strategy designs as a function of sample size (number of randomized patients) for the different scenarios. In scenario1, the power of the randomize-all and targeted designs are identical. In scenario 2, the power of the randomize-all and strategy designs are identical.
Fig. 4
Fig. 4
Illustration for shifting the cutpoint from “cutoff” to “C + Δ ”.
Fig. 5
Fig. 5
Illustration for shifting the marker distribution.
Fig. 6
Fig. 6
Power for testing the overall and the targeted hypothesis in the randomize-all design with α adjusted for multiple comparisons: α = 0.04 for the overall hypothesis and α = 0.01 for the targeted hypothesis (solid lines). For comparison, the dashed lines show the power for α = 0.05 for both hypotheses.
Fig. 7
Fig. 7
Ratio of the number of patients randomized in the randomize-all design and the number of patients screened in the targeted design as a function of marker prevalence.

Similar articles

See all similar articles

Cited by 31 articles

See all "Cited by" articles

Publication types

MeSH terms

Feedback